Immune cell study may unlock clues to better allergy eye treatments
NCT ID NCT07171307
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study examines immune cells in 60 people with allergic conjunctivitis, both those receiving desensitization therapy and those not, plus healthy controls. Researchers will analyze blood and tear samples to measure specific immune markers and cell activity. The goal is to find biological clues that could lead to improved treatments for this common eye allergy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify immune markers that help predict treatment response and guide future therapies for allergic conjunctivitis.
- What could go wrong
- This is an observational study, not a treatment trial. It is small (60 participants) and early, so findings may not lead to direct clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study subjects are patients recruited from the outpatient clinic of "Clinical Immunology" at Instituto de Oftalmologia Conde de Valenciana. All patients are evaluated by specialists in ophthalmology and allergy.
- Ages
-
5 to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects aged between 5 and 30 years, of either sex. * Subjects with a confirmed diagnosis of allergic conjunctivitis. * Presence of active symptoms. * Positive skin tests. * Willingness to participate in the protocol by signing informed consent. Exclusion Criteria: * Subjects who have had an infection within the two months prior to sample collection. * Patients with other active systemic allergic diseases (such as bronchial asthma, dermatitis, among others). * Subjects with chronic-degenerative or autoimmune diseases. * Subjects who have received topical immunosuppressive treatment in the last two months. * Subjects receiving systemic immunosuppressive therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Conjunctivitis, allergic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro
Mexico City, Mexico City, 06800, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.